PMC:7321036 / 129474-130050 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T1775","span":{"begin":139,"end":141},"obj":"SO:0001811"},{"id":"T1776","span":{"begin":173,"end":174},"obj":"SP_6;NCBITaxon:9606"},{"id":"T1785","span":{"begin":207,"end":208},"obj":"NCBITaxon:6239"},{"id":"T1788","span":{"begin":211,"end":212},"obj":"NCBITaxon:9606"},{"id":"T1793","span":{"begin":241,"end":242},"obj":"NCBITaxon:9606"},{"id":"T1802","span":{"begin":336,"end":339},"obj":"SO:0001811"},{"id":"T1804","span":{"begin":453,"end":455},"obj":"CHEBI:32958;CHEBI:32958"},{"id":"T1811","span":{"begin":540,"end":541},"obj":"GO:0006468"},{"id":"T1812","span":{"begin":541,"end":542},"obj":"GO:0043234"},{"id":"T1813","span":{"begin":542,"end":548},"obj":"GO:0043234"},{"id":"T1814","span":{"begin":555,"end":558},"obj":"GO:0043234"},{"id":"T1816","span":{"begin":564,"end":567},"obj":"GO:0032991"},{"id":"T1817","span":{"begin":568,"end":569},"obj":"GO:0032991"}],"text":"The Krogan laboratory has received research support from Vir Biotechnology and F. Hoffmann-La Roche. K.M.S. has consulting agreements for the following companies involving cash and/or stock compensation: Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics (zotatifin and tomivosertib), Erasca, Genentech/Roche, Janssen Pharmaceuticals, Kumquat Biosciences, Kura Oncology, Merck, Mitokinin, Petra Pharma, Qulab Inc. Revolution Medicines (WDB002), Type6 Therapeutics, Venthera, and Wellspring Biosciences (Araxes Pharma)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T212","span":{"begin":22,"end":25},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T213","span":{"begin":108,"end":111},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"The Krogan laboratory has received research support from Vir Biotechnology and F. Hoffmann-La Roche. K.M.S. has consulting agreements for the following companies involving cash and/or stock compensation: Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics (zotatifin and tomivosertib), Erasca, Genentech/Roche, Janssen Pharmaceuticals, Kumquat Biosciences, Kura Oncology, Merck, Mitokinin, Petra Pharma, Qulab Inc. Revolution Medicines (WDB002), Type6 Therapeutics, Venthera, and Wellspring Biosciences (Araxes Pharma)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T53882","span":{"begin":91,"end":93},"obj":"Chemical"}],"attributes":[{"id":"A49416","pred":"chebi_id","subj":"T53882","obj":"http://purl.obolibrary.org/obo/CHEBI_33336"}],"text":"The Krogan laboratory has received research support from Vir Biotechnology and F. Hoffmann-La Roche. K.M.S. has consulting agreements for the following companies involving cash and/or stock compensation: Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics (zotatifin and tomivosertib), Erasca, Genentech/Roche, Janssen Pharmaceuticals, Kumquat Biosciences, Kura Oncology, Merck, Mitokinin, Petra Pharma, Qulab Inc. Revolution Medicines (WDB002), Type6 Therapeutics, Venthera, and Wellspring Biosciences (Araxes Pharma)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T17","span":{"begin":419,"end":427},"obj":"Phenotype"}],"attributes":[{"id":"A17","pred":"hp_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"The Krogan laboratory has received research support from Vir Biotechnology and F. Hoffmann-La Roche. K.M.S. has consulting agreements for the following companies involving cash and/or stock compensation: Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics (zotatifin and tomivosertib), Erasca, Genentech/Roche, Janssen Pharmaceuticals, Kumquat Biosciences, Kura Oncology, Merck, Mitokinin, Petra Pharma, Qulab Inc. Revolution Medicines (WDB002), Type6 Therapeutics, Venthera, and Wellspring Biosciences (Araxes Pharma)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T1025","span":{"begin":0,"end":81},"obj":"Sentence"},{"id":"T1026","span":{"begin":82,"end":100},"obj":"Sentence"},{"id":"T1027","span":{"begin":101,"end":203},"obj":"Sentence"},{"id":"T1028","span":{"begin":204,"end":471},"obj":"Sentence"},{"id":"T1029","span":{"begin":472,"end":576},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The Krogan laboratory has received research support from Vir Biotechnology and F. Hoffmann-La Roche. K.M.S. has consulting agreements for the following companies involving cash and/or stock compensation: Black Diamond Therapeutics, BridGene Biosciences, Denali Therapeutics, Dice Molecules, eFFECTOR Therapeutics (zotatifin and tomivosertib), Erasca, Genentech/Roche, Janssen Pharmaceuticals, Kumquat Biosciences, Kura Oncology, Merck, Mitokinin, Petra Pharma, Qulab Inc. Revolution Medicines (WDB002), Type6 Therapeutics, Venthera, and Wellspring Biosciences (Araxes Pharma)."}